Table 1 Baseline characteristics and prior treatments

From: Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

 

Elranatamab SC monotherapy (n = 55)

Median age, years

64.0 (42–80)

Sex

 

 Female

26 (47.3)

 Male

29 (52.7)

Race

 

 White

37 (67.3)

 Black/African American

11 (20.0)

 Asian

4 (7.3)

 Not reported

3 (5.5)

ECOG PS

 

 0–1

50 (90.9)

 ≥2

5 (9.1)

R-ISS stage at initial diagnosis

 

 Stage I

14 (25.5)

 Stage II

20 (36.4)

 Stage III

11 (20.0)

 Not reported

10 (18.2)

Cytogenetic risk

 

 Higha

16 (29.1)

 Standard

35 (63.6)

 Unknown

4 (7.3)

Extramedullary disease

17 (30.9)

Median number of prior anti-myeloma therapies

5.0 (2–14)

Triple-class refractoryb

50 (90.9)

Refractory to last line of therapy

49 (89.1)

Prior PIs

55 (100.0)

 Bortezomib

52 (94.5)

 Carfilzomib

47 (85.5)

 Ixazomib

18 (32.7)

Prior ImiDs

55 (100.0)

 Lenalidomide

54 (98.2)

 Pomalidomide

52 (94.5)

 Thalidomide

9 (16.4)

 CC-92480

2 (3.6)

 Iberdomide

1 (1.8)

Prior anti-CD38 therapy

54 (98.2)

 Daratumumab

52 (94.5)

 Isatuximab

4 (7.3)

 Otherc

1 (1.8)

Prior BCMA-targeted therapy

13 (23.6)

 Anti-BCMA ADC

4 (7.3)

 CAR-T

5 (9.1)

 Both anti-BCMA ADC and CAR-T

4 (7.3)

  1. Values are median (range) or n (%). Data cutoff was 30 September 2022. Patients may have received more than one treatment within a given therapy class.
  2. aDefinition of high cytogenetic risk includes t(4;14), t(14;16) and del(17p).
  3. bTriple-class refractory disease is refractory to at least one PI, one ImiD and one anti-CD38 therapy.
  4. cOne patient treated at 360 μg kg−1 received prior anti-myeloma therapy with a CD38×CD3 bispecific molecule.
  5. ImiD, immunomodulatory drug; PI, proteasome inhibitor; R-ISS, Revised International Staging System; SC, subcutaneous.
Back to article page